KLAR Partners Acquires BÜHLMANN Laboratories AG
6 June 2024 – On 5 June 2024, the financial investor KLAR Partners Limited acquired all shares in BÜHLMANN Laboratories AG.
BÜHLMANN Laboratories is a Swiss company, located in Schönenbuch, near Basel. Since 1976, the purpose of BÜHLMANN Laboratories is to develop and market specialty, high-quality in-vitro diagnostics and to distribute third-party molecular diagnostics products. BÜHLMANN Laboratories promotes its own products through its affiliates and more than 60 qualified distributors worldwide.
KLAR Partners is a European private equity firm focused on investments in companies operating in business services and industrial technology. The companies in which KLAR Partners invests each have an annual turnover of approximately EUR 50‒500m and are headquartered in the DACH, Nordics, and Benelux regions.
Walder Wyss advised KLAR Partners on the transaction. The team was led by Alex Nikitine (Partner, Corporate/M&A) and Dario Galli (Managing Associate, Corporate/M&A) and included Fabian Akeret (Associate, Corporate/M&A), Erik Lanz (Associate, Corporate/M&A), Maurus Winzap (Partner, Tax), and Janine Corti (Counsel, Tax), as well as Michael Kissling (Senior Associate, Corporate/M&A), Benjamin Reis (Associate, Corporate/M&A), Nadja D. Leuthardt (Senior Associate, Real Estate), Benjamin Sommerhalder (Associate, Real Estate), Celine Weber (Managing Associate, Life Sciences), Hugh Reeves (Managing Associate, IP & IT), Michelle Sollberger (Associate, Employment), Katja Rauber (Associate, Employment), Valentin Freiermuth (Associate, Banking & Finance), Johannes Stamm (Associate, Competition), Marina Srienz (Associate, Corporate/M&A), Bertrand Donzé (Senior Associate, Employment), Thomas Müller (Partner, Banking & Finance), Roger Ammann (Partner, Banking & Finance), Laura Tarenzi (Associate, Banking & Finance), and Suan Jung (Trainee, Corporate/M&A).